Journal of Clinical Oncology, Vol 10, 1723-1729, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia

RA Clift, CD Buckner, FR Appelbaum, G Schoch, FB Petersen, WI Bensinger, J Sanders, KM Sullivan, R Storb and J Singer
Fred Hutchinson Cancer Research Center, Seattle, WA 98104-2092.

PURPOSE: The purpose of this report was to review the Seattle experience in bone marrow transplantation (BMT) for acute myeloid leukemia (AML) during untreated first relapse. PATIENTS AND METHODS: Through 1990, 126 patients were transplanted during untreated first relapse of AML. Several preparative regimens were used, two of which involved more than 20 patients. Regimen 1 (29 patients) consisted of cyclophosphamide (CY) 120 mg/kg and 15.75 Gy of fractionated total-body irradiation (TBI) with methotrexate (MTX) given intermittently during a 102-day period to prevent graft-versus-host disease (GVHD). Regimen 2 (22 patients) consisted of the same CY and TBI treatment and a combination of MTX and cyclosporine (CSP) for GVHD prophylaxis. The remaining 75 patients were treated with 17 other transplant regimens. Outcome was compared for patients who were treated with regimen 1, regimen 2, and any other regimen. RESULTS: The 5-year probabilities of relapse-free survival (RFS), relapse, and nonrelapse mortality for 126 patients were .23, .57, and .44, respectively. With regimen 1, relapse (.26) was significantly less than for regimen 2 (.70; P = .004) or any other regimen (.76; P = .004). Regimen 1 patients developed more acute GVHD (.67) than regimen 2 patients (.26; P = .02) or patients on other regimens (.41; P = .02), and had increased nonrelapse mortality. Nevertheless, regimen 1 patients had a significantly higher 3-year RFS (.38) than those treated with regimen 2 (.18; P = .04) or any other regimen (.20; P = .05). CONCLUSIONS: For patients who received 120 mg/kg CY and 15.75 Gy TBI, relapse incidence was less and survival was better after GVHD prophylaxis with MTX alone than after a combination of MTX and CSP, despite a significantly higher incidence of acute GVHD. The results of treatment with regimen 1 justify future studies of the optimal timing of allogeneic BMT in the treatment of patients with AML.

This article has been cited by other articles:

				F. R. Appelbaum Indications for Hematopoietic Cell Transplantation for the Treatment of Adult Acute Leukemia ASCO Educational Book, January 1, 2008; 2008(1): 325 - 329. [Abstract] [Full Text] [PDF]

				C. Schmid, M. Schleuning, R. Schwerdtfeger, B. Hertenstein, E. Mischak-Weissinger, D. Bunjes, S. v. Harsdorf, C. Scheid, U. Holtick, H. Greinix, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation Blood, August 1, 2006; 108(3): 1092 - 1099. [Abstract] [Full Text] [PDF]

				D. W. Milligan, K. Wheatley, T. Littlewood, J. I. O. Craig, A. K. Burnett, and for the NCRI Haematological Oncology Clinical Stud Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial Blood, June 15, 2006; 107(12): 4614 - 4622. [Abstract] [Full Text] [PDF]

				J. E. Sanders, K. A. Guthrie, P. A. Hoffmeister, A. E. Woolfrey, P. A. Carpenter, and F. R. Appelbaum Final adult height of patients who received hematopoietic cell transplantation in childhood Blood, February 1, 2005; 105(3): 1348 - 1354. [Abstract] [Full Text] [PDF]

				J. M. Allan, A. G. Smith, K. Wheatley, R. K. Hills, L. B. Travis, D. A. Hill, D. M. Swirsky, G. J. Morgan, and C. P. Wild Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy Blood, December 15, 2004; 104(13): 3872 - 3877. [Abstract] [Full Text] [PDF]

				I. A. Tabbara, K. Zimmerman, C. Morgan, and Z. Nahleh Allogeneic Hematopoietic Stem Cell Transplantation: Complications and Results Arch Intern Med, July 22, 2002; 162(14): 1558 - 1566. [Abstract] [Full Text] [PDF]

				B. R. Blazar, A. M. Krieg, and P. A. Taylor Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients Blood, August 15, 2001; 98(4): 1217 - 1225. [Abstract] [Full Text] [PDF]

				A. E. Woolfrey, T. A. Gooley, E. L. Sievers, L. A. Milner, R. G. Andrews, M. Walters, P. Hoffmeister, J. A. Hansen, C. Anasetti, E. Bryant, et al. Bone Marrow Transplantation for Children Less Than 2 Years of Age With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Blood, November 15, 1998; 92(10): 3546 - 3556. [Abstract] [Full Text] [PDF]

				P. Zikos, M.T. Van Lint, F. Frassoni, T. Lamparelli, F. Gualandi, D. Occhini, N. Mordini, G. Berisso, S. Bregante, F. De Stefano, et al. Low Transplant Mortality in Allogeneic Bone Marrow Transplantation for Acute Myeloid Leukemia: A Randomized Study of Low-Dose Cyclosporin Versus Low-Dose Cyclosporin and Low-Dose Methotrexate Blood, May 1, 1998; 91(9): 3503 - 3508. [Abstract] [Full Text] [PDF]

				Z. S. Pavletic and J. O. Armitage Bone Marrow Transplantation for Cancer--An Update Oncologist, June 1, 1996; 1(3): 159 - 168. [Abstract] [Full Text] [PDF]

				A. A. Morley, H. Ghaddar, P. Anderlini, E. Estey, B. Meisenberg, R. Zittoun, F. Mandelli, and S. Suciu Treatment of Acute Myelogenous Leukemia N. Engl. J. Med., June 22, 1995; 332(25): 1717 - 1719. [Full Text]

				C.-H. Pui Childhood Leukemias N. Engl. J. Med., June 15, 1995; 332(24): 1618 - 1630. [Full Text] [PDF]

				R. A. Zittoun, F. Mandelli, R. Willemze, T. de Witte, B. Labar, L. Resegotti, F. Leoni, E. Damasio, G. Visani, G. Papa, et al. Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous Leukemia N. Engl. J. Med., January 26, 1995; 332(4): 217 - 223. [Abstract] [Full Text] [PDF]

				J. O. Armitage Bone Marrow Transplantation N. Engl. J. Med., March 24, 1994; 330(12): 827 - 838. [Full Text]